Quarterly report pursuant to Section 13 or 15(d)

Corporate Information - Narrative (Details)

v3.22.2
Corporate Information - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
May 31, 2013
Business Acquisition [Line Items]            
Cash, cash equivalents and investments $ 80,900   $ 80,900      
Net loss 10,338 $ 15,498 15,439 $ 19,670    
Accumulated deficit $ 272,583   $ 272,583   $ 257,144  
Pieris Pharmaceuticals GmbH            
Business Acquisition [Line Items]            
Ownership interest acquired (as a percent)           100.00%